173 related articles for article (PubMed ID: 36179986)
1. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Lin C; Sajeev G; Stiff PJ; Brunstein CG; Cutler C; Sanz G; Lindemans CA; Rezvani AR; Hanna R; Koh LP; Maziarz RT; Hwang WYK; Song Y; Liu Q; Manghani R; Sivaraman S; Signorovitch J; Horwitz ME; Sung AD
Transplant Cell Ther; 2023 Jan; 29(1):52.e1-52.e9. PubMed ID: 36179986
[TBL] [Abstract][Full Text] [Related]
2. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
3. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial.
Majhail NS; Miller B; Dean R; Manghani R; Shin H; Sivaraman S; Maziarz RT
Transplant Cell Ther; 2023 Dec; 29(12):749.e1-749.e5. PubMed ID: 37703995
[TBL] [Abstract][Full Text] [Related]
4. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U
Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220
[TBL] [Abstract][Full Text] [Related]
5. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz ME; Stiff PJ; Cutler C; Brunstein C; Hanna R; Maziarz RT; Rezvani AR; Karris NA; McGuirk J; Valcarcel D; Schiller GJ; Lindemans CA; Hwang WYK; Koh LP; Keating A; Khaled Y; Hamerschlak N; Frankfurt O; Peled T; Segalovich I; Blackwell B; Wease S; Freedman LS; Galamidi-Cohen E; Sanz G
Blood; 2021 Oct; 138(16):1429-1440. PubMed ID: 34157093
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
Parikh S; Brochstein JA; Galamidi E; Schwarzbach A; Kurtzberg J
Blood Adv; 2021 Feb; 5(3):843-852. PubMed ID: 33560399
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin C; Schwarzbach A; Sanz J; Montesinos P; Stiff P; Parikh S; Brunstein C; Cutler C; Lindemans CA; Hanna R; Koh LP; Jagasia MH; Valcarcel D; Maziarz RT; Keating AK; Hwang WYK; Rezvani AR; Karras NA; Fernandes JF; Rocha V; Badell I; Ram R; Schiller GJ; Volodin L; Walters MC; Hamerschlak N; Cilloni D; Frankfurt O; McGuirk JP; Kurtzberg J; Sanz G; Simantov R; Horwitz ME
Transplant Cell Ther; 2023 May; 29(5):338.e1-338.e6. PubMed ID: 36775201
[TBL] [Abstract][Full Text] [Related]
8. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
[TBL] [Abstract][Full Text] [Related]
9. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.
De Sa H; Maziarz RT; Gandhi AP
Expert Opin Biol Ther; 2024 Mar; 24(3):139-146. PubMed ID: 38481366
[TBL] [Abstract][Full Text] [Related]
10. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
11. [Umbilical cord blood as a source of stem cells].
Bojanić I; Golubić Cepulić B
Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.
Gómez-Santos C; González-Vicent M; Molina B; Deltoro N; Herrero B; Ruiz J; Pérez-Martínez A; Diaz MA
World J Pediatr; 2021 Dec; 17(6):609-618. PubMed ID: 34590210
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes.
Cusatis RN; Tecca HR; D'Souza A; Shaw BE; Flynn KE
Cancer; 2020 Jun; 126(11):2679-2686. PubMed ID: 32154926
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
16. Randomized Controlled Trial of Isha Kriya versus Observation to Improve Quality of Life in Hematopoietic Cell Transplantation Recipients.
Chopra M; Naik RR; Naik R; Sahni J; Bala K; Ahlawat J; Anand A; Singh C; Jandial A; Jain A; Prakash G; Khadwal A; Malhotra P; Lad DP
Transplant Cell Ther; 2023 Aug; 29(8):530.e1-530.e5. PubMed ID: 37192731
[TBL] [Abstract][Full Text] [Related]
17. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.
Shaw BE; Brazauskas R; Millard HR; Fonstad R; Flynn KE; Abernethy A; Vogel J; Petroske C; Mattila D; Drexler R; Lee SJ; Horowitz MM; Rizzo JD
Cancer; 2017 Dec; 123(23):4687-4700. PubMed ID: 28817182
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
19. Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
Tay J; Allan DS; Chatelain E; Coyle D; Elemary M; Fulford A; Petrcich W; Ramsay T; Walker I; Xenocostas A; Tinmouth A; Fergusson D
J Clin Oncol; 2020 May; 38(13):1463-1473. PubMed ID: 32083994
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
